Near-Term Milestones
Clinical Programs
- Complete one of our two Phase II “proof of concept” programs with alfimeprase by year-end 2003
- Full publication of Phase I alfimeprase data in medical journal
- Presentation of Phase I alfimeprase data at the AIM Symposium
- Identify additional clinical candidates from Nuvelo genes
Secure strategic partners for antibody target and secreted protein programs
Successfully divest Variagenics and Callida assets